Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021
Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), held its annual general meeting (“AGM”) at which the following principal resolutions were passed.
Adoption of income statement and balance sheet for the financial year 2020 and discharge from liability
The AGM resolved to adopt the income statements for the financial year 2020 as well as the balance sheets as of 31 December 2020, as set out in the annual report for the Company and the group. The members of the Board of Directors and the managing director were discharged from liability for the financial year 2020.
Allocation of profit or loss
The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2020 and that the results of the Company shall be carried forward.
Election of board members, auditors, fees to the Board of Directors and auditors
The AGM resolved, in accordance with the nomination committee’s proposal, that the number of members of the Board of Directors shall be eight without deputies and that the number of auditors shall be one registered accounting firm.
In accordance with the nomination committee’s proposal Lennart Jeansson was elected as new member of the Board of Directors and Alain Herrera, Anna Belfrage, Aram Mangasarian, Magnus Björsne, Paula Boultbee, Pär-Ola Mannefred and Robert Marchesani were re-elected as members of the Board of Directors, all for the period until the end of the next AGM. Pär-Ola Mannefred was re-elected as the chairman of the Board of Directors.
The audit firm KPMG AB was re-elected as auditor of the Company, with Jan Malm as auditor-in-charge, for the period until the end of the next AGM.
The AGM further resolved to, in accordance with the nomination committee’s proposal, that fees to the chairman of the board shall be paid with SEK 550,000, to members of the board who are not employed within the Company with SEK 250,000, to the chairman of the audit committee with SEK 75,000, to each of the other members of the audit committee with SEK 40,000, to the chairman of the remuneration committee with SEK 50,000 and to each of the other members of the remuneration committee with SEK 25,000.
The AGM further resolved, in accordance with the nomination committee’s proposal, that board members that board members (in addition to remuneration for expenses relating to travel and accommodation) domiciled in Europe, but outside the Nordic countries, shall receive a remuneration of SEK 7,500 per physical board meeting and board members domiciled in North America shall receive a remuneration of SEK 15,000 per physical board meeting.
The AGM further resolved, in accordance with the nomination committee’s proposal, that the remuneration to the auditor of the Company shall be paid in accordance with approved statement of costs.
Principles for the appointment of the nomination committee
The AGM resolved, in accordance with the nomination committee’s proposal, that the principles for appointment of a nomination committee as adopted at the annual general meeting 2020 and as presented in the convening notice would remain unchanged.
Approval of the Board of Directors’ remuneration report
The AGM resolved, in accordance with the proposal from the board of directors, to approve the remuneration report for the financial year 2020.
Amendment of the articles of association
The Board of Directors’ proposal to amend the articles of association did not achieve the required majority, hence, the proposal was not adopted by the AGM.
Authorisation for the Board of Directors to resolve on issues
The Board of Directors’ proposal regarding issue authorisation to the Board of Directors, did not achieve the required majority, hence, the proposal was not adopted by the AGM.
For more information, please contact
Isofol Medical AB (publ)
Pär-Ola Mannefred, chairman of the Board of Directors
E-mail: par-ola.mannefred@residenset.se
Phone: +46 (0)705-12 70 17
Jarl Ulf Jungnelius, M.D.
Email: jungnelius@isofolmedical.com
Phone: +46 (0)709-16 89 55
Certified Adviser
FNCA Sweden AB
E-mail: info@fnca.se
Phone: +46 (0)8-528 003 99
The information was submitted for publication, through the agency of the contact person set out above, at 18:10 CEST on June 23, 2021.
About arfolitixorin
Arfolitixorin is Isofol’s proprietary drug candidate that is developed to improve the efficiency of 5-FU based (folate-based) chemotherapy primary for advanced colorectal cancer. Arfolitixorin is currently being evaluated in a global phase III-study, AGENT. Arfolitixorin is the active end product of extensively used folate-based drugs and can potentially benefit all patients with advanced colorectal cancer, as arfolitixorin does not require metabolic activation to become effective.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a biotech company in late clinical phase developing arfolitixorin to improve standard treatment of 5-FU based chemotherapy primary for advanced colorectal cancer by improve tumour size reduction and extend the life of the cancer patient. Isofol has an exclusive global licensing agreement with Merck KGaA, Darmstadt, Germany, to develop and commercialise arfolitixorin in the field of oncology. Isofol Medical AB (publ) is traded on Nasdaq First North Premier Growth Market. Certified adviser is FNCA Sweden AB.